Dextech Medical AB (NGM:DEX)
Sweden flag Sweden · Delayed Price · Currency is SEK
4.060
+0.020 (0.50%)
At close: Apr 24, 2025
-17.14%
Market Cap 80.97M
Revenue (ttm) 4.24M
Net Income (ttm) -4.63M
Shares Out 18.49M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,834
Average Volume 8,424
Open 4.080
Previous Close 4.040
Day's Range 3.860 - 4.080
52-Week Range 3.540 - 6.350
Beta 1.17
RSI 62.08
Earnings Date Apr 29, 2025

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 1
Stock Exchange Nordic Growth Market
Ticker Symbol DEX
Full Company Profile

Financial Performance

In 2024, Dextech Medical AB's revenue was 5.39 million, a decrease of -38.18% compared to the previous year's 8.71 million. Losses were -4.71 million, 2.51% more than in 2023.

Financial Statements

News

There is no news available yet.